- Home
- BMRC vs PBYI Comparison
BMRC vs PBYI Comparison
Compare BMRC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRC | PBYI |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.3M | 343.9M |
| IPO Year | 2007 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BMRC | PBYI |
|---|---|---|
| Price | $25.62 | $7.12 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.67 | N/A |
| AVG Volume (30 Days) | 106.8K | ★ 263.3K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $391.81 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.25 | $2.85 |
| 52 Week High | $28.48 | $7.90 |
Technical Indicators
Market Signals| Indicator | BMRC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 46.23 |
| Support Level | $25.14 | $7.09 |
| Resistance Level | $27.18 | $7.25 |
| Average True Range (ATR) | 0.81 | 0.35 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 32.06 | 11.76 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.